Teva Pharmaceutical Industries Announces News

Teva Pharmaceutical Industries Ltd. shared today that it plans to release its third quarter 2025 financial results on November 5, 2025, at 7:00 a.m. ET. Following this announcement, Teva will hold a conference call and live webcast at 8:00 a.m. ET on the same day. To participate in this event, interested parties are required to register in advance to receive the necessary phone number and personal pin for access. In addition, a live webcast of the call will be accessible on Teva’s website at https://ir.tevapharm.com/Events-and-Presentations. A replay of the webcast will also be made available on Teva’s website within 24 hours following the call’s conclusion.

Teva Pharmaceutical Industries Ltd. is a prominent biopharmaceutical company with a strong generics division and has been a key player in the industry for over 120 years. Their unwavering commitment to innovation spans across neuroscience, immunology, and the production of complex generic medicines, biosimilars, and pharmacy brands globally. Teva’s primary focus is on meeting the evolving needs of patients today and in the future. The company’s dedication to better health is evident in its diverse range of products and services.

It is important to note the cautionary statement regarding forward-looking statements as outlined by Teva Pharmaceutical Industries Ltd. The content of this document and any related presentations may contain forward-looking statements within the context of the Private Securities Litigation Reform Act of 1995. These statements are based on the current beliefs and expectations of management and are subject to significant risks and uncertainties that could impact the company’s future performance and results. Factors contributing to these potential differences include Teva’s ability to remain competitive in the market, effectively implement its Growth strategy, manage its indebtedness, oversee its operations, adhere to regulatory requirements, and address financial and economic risks, among other considerations.

It is, therefore, advised to exercise caution and not overly rely on forward-looking statements as they speak only to the date of issuance. Teva Pharmaceutical Industries Ltd. does not bear any obligation to update or revise these statements based on new information or future events. Interested parties are encouraged to review Teva’s Quarterly Report on Form 10-Q for the second quarter of 2025 and its Annual Report on Form 10-K for the year ended December 31, 2024, for further insight into potential risk factors and forward-looking statements.